Get the Stockscreener App
6.88
12.58%
-0.99
After Hours:
6.79
-0.09
-1.31%
Cartesian Therapeutics Inc stock is traded at $6.88, with a volume of 223.71K.
It is down -12.58% in the last 24 hours and up +9.55% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$7.87
Open:
$7.9
24h Volume:
223.71K
Relative Volume:
1.33
Market Cap:
$178.90M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.1382
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
-17.60%
1M Performance:
+9.55%
6M Performance:
-35.34%
1Y Performance:
-61.61%
1-Day Range:
$6.86
$7.90
1-Week Range:
$6.86
$8.3999
52-Week Range:
$5.98
$18.80
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.88 | 204.65M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Cartesian Therapeutics (RNAC) to Release Earnings on Thursday - MarketBeat
Published on: 2026-03-02 22:13:30 - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Cartesian Therapeutics to present at TD Cowen Health Care Conference in Boston - Traders Union
RNAC Should I Buy - Intellectia AI
Cartesian Therapeutics, Inc. (RNAC): Biotechnology Innovator With A 350% Potential Upside - DirectorsTalk Interviews
Cartesian Therapeutics, Inc. (RNAC) upgraded to buy: What does it mean for the stock? - MSN
Published on: 2026-02-25 09:47:28 - baoquankhu1.vn
Aug Sentiment: What is the earnings history of Cartesian Therapeutics IncWeekly Market Outlook & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - Bitget
What drives Cartesian Therapeutics Inc.’s stock priceQuarterly Trade Review & Real-Time Buy Zone Alerts - mfd.ru
Institution Moves: What’s the MACD signal for Cartesian Therapeutics Inc.2025 Buyback Activity & Smart Investment Allocation Insights - mfd.ru
Cartesian Therapeutics, Inc. (RNAC) Investor Outlook: Unpacking a 435.71% Potential Upside in Biotech - DirectorsTalk Interviews
Analyst Upgrade: Is Cartesian Therapeutics Inc attractive for institutional investorsEarnings Recap Report & Low Volatility Stock Recommendations - baoquankhu1.vn
Trading Recap: What are Zenas BioPharma Incs growth leversMarket Trend Review & Verified Entry Point Detection - baoquankhu1.vn
Is Cartesian Therapeutics Inc. stock positioned well for digital economyTrade Volume Summary & Community Verified Trade Signals - mfd.ru
Is Cartesian Therapeutics Inc.’s ROE strong enoughWeekly Gains Report & Risk Managed Investment Entry Signals - mfd.ru
FMR LLC Reduces Stake in Cartesian Therapeutics Inc: A Strategic Portfolio Adjustment - GuruFocus
Is Cartesian Therapeutics Inc. a defensive stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Can JCTC stock outperform in a bear market2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 420% Potential Upside in Biotechnology - DirectorsTalk Interviews
Cartesian Therapeutics (RNAC) Issues New Stock Options to Employ - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - marketscreener.com
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 0.6%Here's What Happened - MarketBeat
Will Cartesian Therapeutics (NASDAQ:RNAC) Spend Its Cash Wisely? - Sahm
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Can a 388.62% Upside Fuel Your Investment Strategy? - DirectorsTalk Interviews
Smart Money: Is Cartesian Therapeutics Inc trading at a discountJuly 2025 Trends & Weekly High Return Stock Forecasts - baoquankhu1.vn
Stop Loss: Will Cartesian Therapeutics Inc outperform during market ralliesJuly 2025 Momentum & Real-Time Volume Spike Alerts - baoquankhu1.vn
Aug Mood: Is Cartesian Therapeutics Inc stock a top performer YTDJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Pharma News: Does Cartesian Therapeutics Inc have declining or rising EPSQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-01-22 19:08:46 - mfd.ru
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Risk Check: Is Cartesian Therapeutics Inc benefiting from interest rate changes2025 Biggest Moves & Risk Managed Investment Entry Signals - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
Why Cartesian Therapeutics Inc. stock is a value investor pickMarket Growth Summary & Reliable Price Action Trade Plans - ulpravda.ru
Cartesian Therapeutics (RNAC): Needham Raises Price Target to $4 - GuruFocus
Myasthenia Gravis Market Positioned for Accelerated - openPR.com
Cartesian Therapeutics highlights recent progress and outlines 2026 outlook - marketscreener.com
Cartesian Therapeutics Reports Progress in Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis and Initiates Pediatric Trial for Juvenile Dermatomyositis - Quiver Quantitative
Cartesian Therapeutics Highlights 2026 Strategic Priorities - TradingView — Track All Markets
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewswire
What momentum indicators show for Cartesian Therapeutics Inc. stockQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - Улправда
Is Cartesian Therapeutics Inc. stock resilient to inflationJuly 2025 Final Week & Growth Focused Stock Pick Reports - Улправда
Cartesian Therapeutics (NASDAQ:RNAC) CFO Sells $72,230.62 in Stock - MarketBeat
Is Cartesian Therapeutics Inc. stock supported by innovation pipelineWeekly Stock Report & Free Technical Pattern Based Buy Signals - ulpravda.ru
Cartesian Therapeutics, Inc. (RNAC) Stock Analysis: Exploring a 354.71% Potential Upside in the Biotech Frontier - DirectorsTalk Interviews
Is Cartesian Therapeutics Inc. stock a buy before product launches2026 world cup usa national team quarterfinals defensive leaders transition play group prediction preview - Улправда
Cartesian Therapeutics, Inc.Common Stock (NQ: RNAC - FinancialContent
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):